Attached files
| file | filename |
|---|---|
| EX-99.6 - EXHIBIT 99.6 - Shire plc | may242018-rule29xexhibit996.htm |
| EX-99.5 - EXHIBIT 99.5 - Shire plc | may232018-blocklistingxexh.htm |
| EX-99.4 - EXHIBIT 99.4 - Shire plc | may232018-rule29xexhibit994.htm |
| EX-99.2 - EXHIBIT 99.2 - Shire plc | may222018-rule29xexhibit992.htm |
| EX-99.1 - EXHIBIT 99.1 - Shire plc | may212018-rule29xexhibit991.htm |
| 8-K - 8-K - Shire plc | a8-kxmay242018file.htm |
Exhibit 99.3
Press Release |  |
www.shire.com | |
Director Declaration
May 22, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Olivier Bohuon, Senior Independent Director of the Company, is to be appointed as a Non-Executive Director of Smiths Group plc on July 1, 2018.
This disclosure is made pursuant to LR 9.6.14 of the UK Listing Rules.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations | ||
Christoph Brackmann | christoph.brackmann@shire.com | +41 795 432 359 |
Robert Coates | rcoates@shire.com | +44 203 549 0874 |
Sun Kim | sun.kim@shire.com | +1 617 588 8175 |
Media | ||
Katie Joyce | kjoyce@shire.com | +1 781 482 2779 |
NOTES TO EDITORS
About Shire
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX